Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy.

ABSTRACT:

Background

In our recent clinical trial, the addition of omalizumab to oral immunotherapy (OIT) for milk allergy improved safety, but no significant clinical benefit was detected.

Objective

We sought to investigate mechanisms by which omalizumab modulates immunity in the context of OIT and to identify baseline biomarkers that predict subgroups of patients most likely to benefit from omalizumab.

Methods

Blood was obtained at baseline and multiple time points during a placebo-controlled trial of OIT for milk allergy in which subjects were randomized to receive omalizumab or placebo. Immunologic outcomes included measurement of basophil CD63 expression and histamine release and casein-specific CD4⁺ regulatory T-cell proliferation. Biomarkers were analyzed in r

SUBMITTER: Frischmeyer-Guerrerio PA 

PROVIDER: S-EPMC5632581 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature